Related Experiment Video
Updated: Dec 19, 2025
07:29
Intravascular Delivery of Biologics to the Rat Kidney
Published on: September 1, 2016
8.0K
[Prolonged-release buprenorphine formulations: Perspectives for clinical practice].
Mathieu Chappuy1, Benoit Trojak2, Philippe Nubukpo3
1Service universitaire d'addictologie de Lyon (SUAL), centre hospitalier Le Vinatier, 95, boulevard Pinel, 69678 Bron, France; Service d'addictologie, groupement hospitalier centre, hospices civils de Lyon, 69003 Lyon, France; Centre de soins, d'accompagnement et de prévention en addictologie, groupement hospitalier nord, hospices civils de Lyon, 69004 Lyon, France.
Therapie
|June 5, 2020
Summary
New prolonged-release buprenorphine formulations offer improved safety and comfort for opioid use disorder treatment. These long-acting options aim to reduce risks associated with daily sublingual intake.
Area of Science:
- Pharmacology and Pharmaceutics
- Addiction Medicine
- Drug Delivery Systems
Context:
- Opioid use disorder (OUD) is primarily treated with buprenorphine and methadone.
- Sublingual buprenorphine, while effective, presents challenges like daily adherence, misuse potential, and overdose risk.
- Recent advancements introduce prolonged-release buprenorphine (PRB) formulations to enhance patient care.
Purpose:
- To review the technical characteristics, efficacy, and safety of new prolonged-release buprenorphine formulations.
- To explore patient and professional expectations and concerns regarding these novel treatments.
- To compare subcutaneous implant and depot injection PRB options.
Summary:
- Three PRB formulations are available: a 6-month subcutaneous implant (Sixmo®/Probuphine®) and two depot injections (Sublocade® - monthly, Buvidal®/Brixadi® - weekly/monthly).
- These formulations aim to improve patient comfort, reduce daily adherence burdens, and mitigate risks associated with sublingual buprenorphine.
- PRBs are suitable for initiating treatment or switching from sublingual forms, particularly for stabilized patients or those at risk of dropout.
Impact:
- PRBs may enhance treatment adherence and reduce overdose risks in opioid use disorder.
- Patient and professional acceptance is crucial for the successful integration of these new formulations.
- Long-acting buprenorphine formulations represent a significant evolution in OUD pharmacotherapy.
Keywords:
Action prolongéeBuprenorphineBuprénorphineDépendance aux opioïdesOpiacésOpiatesOpioid dependenceProlonged-releaseSubstitutionMore Related Videos
Related Concept Videos
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
795
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
795
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
135
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
135
01:25Analgesia and Pain Management
1.3K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
1.3K
01:28Biopharmaceutics and Pharmacokinetics: Overview
3.1K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
3.1K
01:27Bioavailability Enhancement: Drug Permeability Enhancement
129
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
129
01:22Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
105
Body:Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug...
105